PharVision Advisers’s Trade Desk TTD Stock Holding History

PharVision Advisers’s Portfolio TTD Stock Details TTD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,486	Closed	-$284K	–	608
2025 Q4	$284K	Buy	+7,486	New	+$332K	0.14%	304

Other funds holding TTD

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PharVision Advisers's TTD Position: Q1 2026 in Review

PharVision Advisers sold out of Trade Desk (TTD) in Q1 2026, closing a stake of 7,486 shares — an estimated $284K sold.

PharVision Advisers first reported a position in TTD in Q4 2025 and held it in 1 quarter. The position peaked at $284K in Q4 2025. 772 funds tracked by Wall St. Rank hold TTD as of Q1 2026.

PharVision Advisers reported no remaining Trade Desk position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 7,486 Trade Desk shares in Q1 2026, an estimated $284K.
PharVision Advisers first reported a position in Trade Desk in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Trade Desk position peaked at $284K in Q4 2025.
772 funds tracked by Wall St. Rank held Trade Desk as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.